Lilly vs Pfizer: Obesity Race Reaches Market Highs
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Choosing your first blue chip crypto involves assessing liquidity, security, and use cases. This starter guide walks you through simple decision criteria.
25,502 articlesLilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
Li Auto unveiled a $1 billion share repurchase after weaker Q4 deliveries, sending LI higher and triggering a debate ...
Seeing a neighbor's Social Security check grow while yours stays the same can feel frustrating. This guide explains t...
Tesla is signaling a profitability-focused future with autonomy and robotics, while BYD drives volume with affordable...
Spotlighting two strong growth names that could exceed Summit Therapeutics in a year. Learn the catalysts, risks, and...
Shimmick's Q1 2026 results offer a window into infrastructure demand and cost pressures. This article breaks down the...
A rising backlog signals durable demand for AI infrastructure. This article digs into what Hewlett Packard Enterprise...
Early-season Vail Resorts skier visits slipped about 20%, yet a major investor is stepping in with a multihundred-mil...
As ELAN reports Q1 2026 earnings, investors want clarity on growth, margins, and guidance. This analysis breaks down ...
Markets opened with caution, nudging major indexes lower as investors weighed earnings and inflation data. This guide...
NOAA expects a very strong El Niño by fall, potentially rivaling the deadliest on record. A hotter, droughtier season...
Unlock a practical, investor-friendly view of arbor realty (abr) earnings. Learn what drives ABR earnings, how to int...